Job Trends
BioSpace data show job postings live increased quarter over quarter, while layoffs fell year over year.
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Career Advice
If workloads aren’t adjusted as needed, the company’s priorities are already compromised. Executive coach Angela Justice explores what happens when goals move forward without removing unnecessary work and what to do about it.
THE LATEST
Takeda CEO Christophe Weber is sticking to his game plan of actively hunting deals that will expand its global presence and create a stronger international profile.
Pfizer will use Arvinas’ proprietary PROTAC Platform to create small molecule therapeutics aimed at degrading disease-causing cellular proteins.
Allergan will cut about 5 percent of its workforce, as the company looks to cut costs due to increased pipeline competition and loss of exclusivity on some products.
The entire 1.2 million-square-feet facility is expected to be finished in 2030.
Celgene has been unloading some of its shares in two of its investments, CRISPR Therapeutics and Atara Biotherapeutics.
A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal.
Investors are salivating at the possibility of a hot merger-and-acquisition market in 2018.
Amgen tapped two companies to receive its coveted 2017 Golden Ticket at LabCentral.
The expansion will nearly double its employment.
Koning has selected Atlanta for its new headquarters and intends to open a new 100,000 square foot facility there.